ProShare Advisors LLC lessened its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 1.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 74,909 shares of the biopharmaceutical company’s stock after selling 1,355 shares during the quarter. ProShare Advisors LLC owned about 0.06% of Celldex Therapeutics worth $185,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CLDX. Vanguard Group Inc. lifted its position in Celldex Therapeutics by 16.4% during the first quarter. Vanguard Group Inc. now owns 9,066,763 shares of the biopharmaceutical company’s stock worth $32,731,000 after buying an additional 1,278,206 shares in the last quarter. Meditor Group Ltd lifted its position in Celldex Therapeutics by 39.9% during the second quarter. Meditor Group Ltd now owns 5,800,000 shares of the biopharmaceutical company’s stock worth $14,326,000 after buying an additional 1,654,100 shares in the last quarter. State Street Corp lifted its position in Celldex Therapeutics by 4.7% during the first quarter. State Street Corp now owns 4,525,051 shares of the biopharmaceutical company’s stock worth $16,341,000 after buying an additional 202,375 shares in the last quarter. Renaissance Technologies LLC lifted its position in Celldex Therapeutics by 42.4% during the first quarter. Renaissance Technologies LLC now owns 1,707,927 shares of the biopharmaceutical company’s stock worth $6,166,000 after buying an additional 508,217 shares in the last quarter. Finally, TSP Capital Management Group LLC lifted its position in Celldex Therapeutics by 6.8% during the second quarter. TSP Capital Management Group LLC now owns 1,135,748 shares of the biopharmaceutical company’s stock worth $2,805,000 after buying an additional 72,500 shares in the last quarter. Institutional investors and hedge funds own 56.69% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.dailypolitical.com/2017/10/16/proshare-advisors-llc-decreases-stake-in-celldex-therapeutics-inc-cldx.html.

Shares of Celldex Therapeutics, Inc. (CLDX) opened at 3.07 on Monday. Celldex Therapeutics, Inc. has a 52-week low of $2.20 and a 52-week high of $5.02. The firm has a 50-day moving average price of $2.76 and a 200-day moving average price of $2.76. The stock’s market cap is $394.01 million.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.05. Celldex Therapeutics had a negative return on equity of 51.87% and a negative net margin of 1,318.94%. The company had revenue of $3.83 million for the quarter, compared to analyst estimates of $1.21 million. During the same quarter in the prior year, the company posted ($0.32) EPS. The business’s revenue for the quarter was up 175.5% compared to the same quarter last year. On average, analysts anticipate that Celldex Therapeutics, Inc. will post ($1.04) EPS for the current fiscal year.

A number of brokerages recently commented on CLDX. Cantor Fitzgerald reiterated a “buy” rating and set a $9.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday, September 26th. ValuEngine downgraded Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. HC Wainwright set a $10.00 price objective on Celldex Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 9th. BidaskClub downgraded Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. Finally, Zacks Investment Research downgraded Celldex Therapeutics from a “buy” rating to a “sell” rating in a research report on Monday, July 17th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $5.88.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.